These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 7492613)
21. The effect of cholestyramine and Mevinolin on the diurnal cycle of rat hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. Tanaka RD; Edwards PA; Lan SF; Knöppel EM; Fogelman AM J Lipid Res; 1982 Sep; 23(7):1026-31. PubMed ID: 6923909 [TBL] [Abstract][Full Text] [Related]
22. Purification and regulation of mevalonate kinase from rat liver. Tanaka RD; Schafer BL; Lee LY; Freudenberger JS; Mosley ST J Biol Chem; 1990 Feb; 265(4):2391-8. PubMed ID: 2153681 [TBL] [Abstract][Full Text] [Related]
24. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver. Keller RK; Zhao Z; Chambers C; Ness GC Arch Biochem Biophys; 1996 Apr; 328(2):324-30. PubMed ID: 8645011 [TBL] [Abstract][Full Text] [Related]
25. Cholesterol biosynthesis from lanosterol. A concerted role for Sp1 and NF-Y-binding sites for sterol-mediated regulation of rat 7-dehydrocholesterol reductase gene expression. Kim JH; Lee JN; Paik YK J Biol Chem; 2001 May; 276(21):18153-60. PubMed ID: 11279217 [TBL] [Abstract][Full Text] [Related]
26. Regulation of squalene epoxidase activity in rat liver. Satoh T; Hidaka Y; Kamei T J Lipid Res; 1990 Nov; 31(11):2095-101. PubMed ID: 2086706 [TBL] [Abstract][Full Text] [Related]
27. Effects of 15-oxa-32-vinyl-lanost-8-ene-3 beta,32 diol on the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase and low density lipoprotein receptor in rat liver. Ness GC; Lopez D; Chambers CM; Zhao Z; Beach DL; Ko SS; Trzaskos JM Arch Biochem Biophys; 1998 Sep; 357(2):259-64. PubMed ID: 9735166 [TBL] [Abstract][Full Text] [Related]
28. Effect of dietary cholesterol and cholestyramine on developmental pattern of 3-hydroxy-3-methylglutaryl-CoA reductase. Alejandre MJ; Ramirez H; Segovia JL; Garcia-Peregrin E Ann Nutr Metab; 1985; 29(2):111-8. PubMed ID: 3994297 [TBL] [Abstract][Full Text] [Related]
29. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381 [TBL] [Abstract][Full Text] [Related]
30. Regulation of the last two enzymatic reactions in cholesterol biosynthesis in rats: effects of BM 15.766, cholesterol, cholic acid, lovastatin, and their combinations. Honda A; Shefer S; Salen G; Xu G; Batta AK; Tint GS; Honda M; Chen TC; Holick MF Hepatology; 1996 Aug; 24(2):435-9. PubMed ID: 8690416 [TBL] [Abstract][Full Text] [Related]
31. Lovastatin exacerbates atypical absence seizures with only minimal effects on brain sterols. Serbanescu I; Ryan MA; Shukla R; Cortez MA; Snead OC; Cunnane SC J Lipid Res; 2004 Nov; 45(11):2038-43. PubMed ID: 15314096 [TBL] [Abstract][Full Text] [Related]
32. Selective inhibition of mammalian lanosterol 14 alpha-demethylase by RS-21607 in vitro and in vivo. Swinney DC; So OY; Watson DM; Berry PW; Webb AS; Kertesz DJ; Shelton EJ; Burton PM; Walker KA Biochemistry; 1994 Apr; 33(15):4702-13. PubMed ID: 8161528 [TBL] [Abstract][Full Text] [Related]
33. Total enzymic synthesis of cholesterol from lanosterol. Cytochrome b5-dependence of 4-methyl sterol oxidase. Fukushima H; Grinstead GF; Gaylor JL J Biol Chem; 1981 May; 256(10):4822-6. PubMed ID: 7228857 [TBL] [Abstract][Full Text] [Related]
34. Lanosterol 14 alpha-demethylase (cytochrome P-45014DM): modulation of its enzyme activity by cholesterol feeding. Sonoda Y; Amano C; Endo M; Sato Y; Sekigawa Y; Fukuhara M Biol Pharm Bull; 1995 Jul; 18(7):1009-11. PubMed ID: 7581240 [TBL] [Abstract][Full Text] [Related]
35. Effect of 3,4-di(OH)-cinnamate synthetic derivative on plasma and hepatic cholesterol level and antioxidant enzyme activities in high cholesterol-fed rats. Park EJ; Lee S; Jeong TS; Bok SH; Lee MK; Park YB; Choi MS J Biochem Mol Toxicol; 2004; 18(5):279-87. PubMed ID: 15549704 [TBL] [Abstract][Full Text] [Related]
36. Lanosterol analogs: dual-action inhibitors of cholesterol biosynthesis. Frye LL; Leonard DA Crit Rev Biochem Mol Biol; 1999; 34(2):123-40. PubMed ID: 10333389 [TBL] [Abstract][Full Text] [Related]
37. Smith-Lemli-Opitz syndrome produced in rats with AY 9944 treated by intravenous injection of lipoprotein cholesterol. Chambers CM; McLean MP; Ness GC Am J Med Genet; 1997 Jan; 68(3):322-7. PubMed ID: 9024567 [TBL] [Abstract][Full Text] [Related]
38. Effect of estrogens on beta-hydroxy-beta-methylglutaryl coenzyme A reductase activity and cholesterol levels. Abul-Hajj YJ Steroids; 1981 Jun; 37(6):601-7. PubMed ID: 7292535 [TBL] [Abstract][Full Text] [Related]
39. Normal and inhibited cholesterol synthesis in the cultured rat embryo. Llirbat B; Wolf C; Chevy F; Citadelle D; Bereziat G; Roux C J Lipid Res; 1997 Jan; 38(1):22-34. PubMed ID: 9034197 [TBL] [Abstract][Full Text] [Related]
40. Reproducing abnormal cholesterol biosynthesis as seen in the Smith-Lemli-Opitz syndrome by inhibiting the conversion of 7-dehydrocholesterol to cholesterol in rats. Xu G; Salen G; Shefer S; Ness GC; Chen TS; Zhao Z; Tint GS J Clin Invest; 1995 Jan; 95(1):76-81. PubMed ID: 7814648 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]